Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Collaboration › Details

Ionis Pharmaceuticals–JPMorgan Chase: investor conference, 202401 supply service Ionis presents at JP Morgan Healthcare Conference 2024

 

Period Period 2024-01-08
Region Region San Francisco, CA
  Country United States (USA)
Organisations Partner, 1st Ionis Pharmaceuticals Inc. (Nasdaq: IONS)
  Group Ionis Pharmaceuticals (Group)
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco
  Product 2 RNA-targeting small molecule drugs (rSMs)
Persons Person Monia, Brett P. (Ionis Pharmaceuticals 202312 CEO formerly 201810 COO + SVP Translational Medicine)
  Person 2 Walke, D. Wade (Ionis Pharmaceuticals 202312 Investor Relations)
     

Ionis Pharmaceuticals, Inc.. (12/20/23). "Press Release: Ionis to Present at 42nd Annual J.P. Morgan Healthcare Conference". Carlsbad, CA.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.

A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionispharma.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.


About Ionis Pharmaceuticals

For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.

To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.


Ionis Investor Contact: D. Wade Walke, Ph.D., info@ionisph.com, 760-603-2331; Ionis Media Contact: Hayley Soffer, ionis_ca@ionisph.com, 760-603-4679

   
Record changed: 2023-12-23

Advertisement

Picture Demy-Colton BioFuture 2024 NYC 3 Healthcare Revolution 650x200px

More documents for Ionis Pharmaceuticals (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2024 NYC Reimagine Healthcare 650x300px




» top